Clinical trial · Interventional
sdAb-based TRNT of Multiple Myeloma: a Feasibility Study
sdAb-based Targeted Radionuclide Therapy of Multiple Myeloma: a Feasibility Study
NCT03956615CI-TRIAL-00055324MUMcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling and bone marrow analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Clinically Suspected or Pathologically Confirmed Multiple Myeloma.
- description
- Patients with a clinically suspected or pathologically confirmed multiple myeloma.
- interventionNames
- Other: Blood sampling and bone marrow analysis
Primary outcomes (2)
- measure
- Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.
- timeFrame
- Within 2 years after study completion
- description
- Reporting of the relative amount of patients for whom such sdAb could be successfully obtained
- measure
- Amount of Paraprotein-targeting sdAbs Generated Per Patient
- timeFrame
- Within 2 years after study completion
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients will only be included in the study if they meet all of the following criteria: * Patients who have given informed consent * Patients at least 18 years old * Patients scheduled to undergo bone marrow sampling in clinical routine because of a clinically suspected or pathologically confirmed multiple myeloma. Exclusion Criteria: Patients will not be included in the study if one of the following criteria applies: * Patients who cannot communicate reliably with the investigator * Patients who are unlikely to cooperate with the requirements of the study * Patients at increased risk of death from a pre-existing concurrent illness * Patients who participated already in part I of this study
References
Publications (0)
Data not yet available
No reference posted for this study.